Health Robotics Submits i.v.STATION and CytoCare Hospital Outcomes, and Launches i.v.STATION ONCO at EAHP 2011

BOZEN, Sud-Tirol, Italy, March 31, 2011 - Health Robotics reported overwhelming success at the European Association
of Hospital Pharmacists (EAHP) 2011 Annual Symposium in Vienna, where its
Executive VP Gaspar DeViedma was invited to publicly share the clinical,
financial, and throughput/efficiency results at 45 of Health Robotics' global
installations for two of its industry-leading robots: i.v.STATION and
CytoCare.

Mr. DeViedma first thanked the hospital participants in the i.v.STATION
Beta-Test program that successfully ended in January 2011, and afterwards
shared the results of the production installations that followed the
completion of the Beta-Tests. Outcomes included an average throughput of 35
patient-specific IV doses per hour [median IV dose compounded, auto-labeled
and auto-capped in 1 minute 45 seconds; fastest IV dose in 1 minute 15
seconds], an average ROI of 6 months, no labeling errors, no drug-exchange
errors, no drug-diluent errors, no reported cross-contamination, 100% success
in sterility and ISO-5 air quality tests, and ISO7886-1 compliant accuracy in
drug quantity.

"i.v.STATION hospitals' recently hosting visits have been very successful
in proving i.v.STATION's flexibility, features, and benefits in a production
environment. With both i.v.STATION and i.v.SOFT Assist now at productive use,
prospective customers and industry experts can now verify Health Robotics'
acclaimed total vision to expand beyond Oncology Automation in a production
environment. An additional benefit from these successful outcomes is our
ability to re-use most of the fully-tested i.v.STATION tools with our
second-generation robot: i.v.STATION ONCO, well before any of our competitors
are able to prove their 20+ year-old fictional claims that they can handle
chemotherapy automation" stated Gaspar DeViedma, Health Robotics' Executive
Vice President.

Mr. DeViedma's presentation and Q&A session [including the IV bags,
bottles, syringes, needles, syringe caps, drugs, diluents, throughput, and
costs supported and/or exhibited by Health Robotics at the 45 robot
installations] is available for download [authorization required] at
www.health-robotics.com/en/about-health-robotics/qa-sessions/

Mr. DeViedma followed its keynote address with the introduction of Health
Robotics' new Cancer Therapy robot: i.v.STATION ONCO, including its
like-for-like clinical, financial, and efficiency/throughput benefits now
enjoyed by i.v.STATION customers. Mr. DeViedma additionally shared with EAHP
Symposium participants the clinical and throughput/efficiency outcomes also
experienced at American, European, and Asia-Pacific hospitals with Health
Robotics' first Cancer Therapy robot: CytoCare; all of the above within the
context of Health Robotics' All-Digital I.V. Room of the Future.

In conclusion, Mr. DeViedma remarked: "Health Robotics is very thankful
to the global i.v.STATION Betas, specially those in America that had the
patience to endure the installation delays directly related to the refusal by
the now-terminated Health Robotics' ex-distributors in the USA to participate
in the Beta-Test installations, and the subsequent need for Health Robotics
to hire local engineering staff. Whether these sites already replaced their
Beta Test robots with purchased robots that are now in production; or have
recently purchased replacement robots and are in the process of installing
production versions; or understandably so, gave up on the project due to the
above-mentioned delays with our ex-distributors; or are waiting for budget
approval; all of us at Health Robotics really appreciate their collective
feedback and dedication during the Beta Tests. In the end, i.v.STATION has
matured much faster than any technology in the history of the IV Robotics and
Automation Industry in great part due to the support of these Beta Sites.
Health Robotics looks forward to repeat this Beta-Test experience with our
upcoming i.v.STATION ONCO and TPNstation robots in 2011 and 2012, this time
without yielding partial control of the Beta-Test processes to Health
Robotics' distribution partners, and thus ensuring completion of the projects
on a timely basis".

About Health Robotics:

Health Robotics is the undisputed global leading supplier of
life-critical intravenous medication robots, providing over 175 hospital
installations in 5 continents with robotics technology and software
automation solutions deployed utilizing virtual high-availability technology.
Its world-leading solutions CytoCare(R) and i.v.STATION(R) ONCO [hazardous
IVs], i.v.STATION(R) [non-hazardous IVs], i.v.SOFT(R) [workflow engine for
manual compounding], MEDarchiver(R) [life-critical clinical information
system], and TPNstation(TM) [totally-automated parenteral nutrition] have and
will greatly contribute to ease hospitals' growing pressures to improve
patient safety, increase throughput and contain costs. Through the effective
and efficient production of sterile, accurate, tamper-evident and
ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate
life-threatening drug and diluent exchange errors, decrease other medical
mistakes and sterility risks, work more efficiently, reduce waste and
controlled substances' diversion, and diminish the gap between rising patient
volume/acuity and scarce medical, nursing, and pharmacy staff. For more
information, please visit: www.health-robotics.com

    For additional information, please contact:
    Claudia Flaim, Marketing Coordinator
    flaim@health-robotics.com
    Phone: +39-0471-200-372

For additional information, please contact: Claudia Flaim, Marketing Coordinator, flaim at health-robotics.com, Phone: +39-0471-200-372